pulmonary arterial hypertension

January 22, 2016January 22, 2016

British Biotech Receives £1.5M to Develop, License New PAH Treatments

A new Cambridge, England-based biotech company called Morphogen-IX received £1.5 million pounds — or about $2.14 million in U.S. dollars — in seed funding to develop a potential new treatment ... Read more

December 9, 2015December 9, 2015

PAH Cell Therapy Shows Safety, Effectiveness in Phase 1 Study

News

Pluristem Therapeutics, Inc. has received notice from United Therapeutics Corp. ending its licensing agreement to develop PLX-PAD for the treatment of pulmonary arterial hypertension (PAH). According to a press release, Pluristem, ... Read more

December 4, 2015December 4, 2015

PAH Patients in Ontario Want Opsumit in Public Drug Plan

News, Pulmonary Hypertension

Canadians living with pulmonary arterial hypertension (PAH) — a rare, progressive lung disease — gathered at Queen’s Park in Ontario recently to urge their province’s health minister, Dr. Eric Hoskins, to publicly ... Read more

November 13, 2015November 16, 2015

Complexa’s CXA-10 To Be Tested as PAH Therapy in Upcoming Round of Phase 2 Trials

News, Pulmonary Hypertension

Complexa Inc., a biopharmaceutical company developing therapies for fibrosis and inflammation-associated orphan conditions, recently announced the conclusion of a broad Phase 1 clinical development program for its drug candidate CXA-10, as ... Read more

November 5, 2015November 9, 2015

COPD Exacerbations Linked to Increased Levels of Lung Neuropeptide

COPD, News

Increased levels of serum vasoactive intestinal peptide were found to be associated with acute exacerbations in patients with chronic obstructive pulmonary disease (COPD), according to the findings of a recent ... Read more

October 23, 2015November 5, 2015

New PAH Trial Results for Selexipag Therapy to Be Presented by Actelion at CHEST 2015

News, Pulmonary Hypertension

Actelion, Ltd., a biopharmaceutical company headquartered in Switzerland and focused on the discovery, development, and commercialization of innovative treatments for unmet medical needs, recently announced that additional important results from its pivotal Phase ... Read more

October 5, 2015November 5, 2015

FDA Approves Combination Therapy of Gilead’s Letairis® Plus Eli Lilly’s Adcirca for patients with Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

Gilead Sciences, recently announced that the FDA has approved of the use of Letairis® (ambrisentan) combined with tadalafil (marketed for PAH under the brand name Adcirca by Eli Lilly) to treat patients with ... Read more

September 30, 2015November 5, 2015

Bellerophon Reveals Positive Data on INOpulse Inhaled Nitric Oxide Therapy for Pulmonary Arterial Hypertension-Associated COPD

News, Pulmonary Hypertension

On September 30, Bellerophon Therapeutics published results from clinical trials performed for investigational therapy INOpulse® on patients with pulmonary arterial hypertension (PAH) associated with chronic obstructive pulmonary disease (COPD). The results were ... Read more

September 30, 2015November 5, 2015

Calcilytics Explored as Potential Drug Candidates for Pulmonary Arterial Hypertension Treatment

News, Pulmonary Hypertension

In a paper recently published in the PLOS ONE journal entitled “Inhibition of Excessive Cell Proliferation by Calcilytics in Idiopathic Pulmonary Arterial Hypertension,” researchers from Kinjo Gakuin University in Japan demonstrated ... Read more

September 28, 2015November 5, 2015

Bellerophon Makes Two Important Announcements For Pulmonary Arterial Hypertension Therapy Program INOpulse

News, Pulmonary Hypertension

Last week, Bellerophon Therapeutics, Inc., (Nasdaq:BLPH), a clinical-stage biotherapeutics company focused on developing therapies that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases, made two ... Read more